| dc.contributor.author | Bousquet, J; Toumi, M; Sousa-Pinto, B; Anto, JM; Bedbrook, A; Czarlewski, W; Valiulis, A; Ansotegui, IJ; Bosnic-Anticevich, S; Brussino, L; Canonica, W; Cecchi, L; Cherrez-Ojeda, I; Chivato, T; Costa, EM; Cruz, AA; Del Giacco, S; Fonseca, JA; Gemicioglu, B; Haahtela, T; Ivancevich, JC; Jutel, M; Kaidashev, I; Klimek, L; Kvedariene, V; Kuna, P; Larenas-Linnemann, DE; Lipworth, B; Morais-Almeida, M; Mullol, J; Papadopoulos, NG; Patella, V; Pham-Thi, N; Regateiro, FS; Rouadi, PW; Samolinski, B; Sheikh, A; Taborda-Barata, L; Ventura, MT; Yorgancioglu, A; Zidarn, M; Zuberbier, T | |
| dc.description.abstract | Drug repurposing is a major field of value-added medicine. It involves investigating and evaluating existing drugs for new therapeutic purposes that address unmet healthcare needs. Several unmet needs in allergic rhinitis could be improved by drug repurposing. This could be game-changing for disease management. Current medications for allergic rhinitis are centered on continuous long-term treatment, and medication registration is based on randomized controlled trials carried out for a minimum of 14 days with adherence of 70% or greater. A new way of treating allergic rhinitis is to propose as-needed treatment depending on symptoms, rather than classical continuous treatment. This rostrum will discuss existing clinical trials on as-needed treatment for allergic rhinitis and real-world data obtained by the mobile health app MASK-air, which fo-cuses on digitally-enabled, patient-centered care pathways. (c) 2022 American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2022;10:2878-88) | |
